🔗 Share this article

While the US continues making unprecedented adjustments to its immunization guidelines, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccinations in the global health crisis and has concentrated on possible fatalities following Covid vaccination in her short time at the FDA.

Proposed Overhauls to Childhood Immunization Program

Agency leaders planned to announce sweeping revisions to the childhood immunization program in December, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of alignment with many the world with little proof for public health gain. The planned update has been delayed until the new year.

Rather than Vinay Prasad, Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for halting specific childhood vaccine recommendations in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – usually the purview of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Background

Dr. Høeg has little discernible experience in medication creation, approval processes or administrative roles, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the kind of background that former directors who ran the center have had.”

This division has an vast portfolio at the agency, Woodcock pointed out.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those need to be looked after,” Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant management aspect to the position, which manages over 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official said.

Official Statement and Controversial Initiatives

When asked about concerns about Høeg’s credentials and whether this selection indicates more teamwork among FDA leaders on vaccines, a spokesperson stated that the “concerns rely on inaccurate assumptions”.

“Her resume matches the functions of her position,” the official said, noting the period Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious one-day medication authorization process that apparently troubled her predecessors. “By what process are these medications being chosen for this fast-track system? Who takes the calls?” Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Documented Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, track record, Howard said. She released a analysis using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are riskier than they are.

Among her “policy goals” for the incoming administration included revising rules for new vaccines and halting “optional” vaccines, she said after the election on a online show. At the FDA, Dr. Høeg has allegedly suggested preventing young men from getting COVID-19 vaccinations.

“She is an complete ideologue who starts off with her beliefs and tailors the evidence to accommodate the data in a extremely deceptive, fraudulent manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|